Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565–79.

Article  CAS  PubMed  Google Scholar 

Wong FL, Francisco L, Togawa K, Bosworth A, Gonzales M, Hanby C, et al. Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns. Blood. 2010;115:2508–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pidala J, Kurland B, Chai XY, Majhail N, Weisdorf D, Pavletic S, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117:4651–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389–401.e381.

Article  Google Scholar 

Kitko CL, White ES, Baird K. Fibrotic and sclerotic manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2012;18:S46–52.

Article  Google Scholar 

MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129:13–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vadakkel G, Eng S, Proli A, Ponce DM. Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era. Bone Marrow Transpl. 2024;59:1360–8.

Article  Google Scholar 

Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA, et al. National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis. Biol Blood Marrow Transpl. 2013;19:632–9.

Article  Google Scholar 

Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023;388:2338–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arora M, Cutler CS, Jagasia MH, Pidala J, Chai X, Martin PJ, et al. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2016;22:449–55.

Article  Google Scholar 

Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transpl. 2015;21:984–99.

Article  Google Scholar 

Flowers MED, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Depoil D, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111:16814–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Flynn R, Paz K, Du J, Reichencbach DK, Taylor PA, Panoskaltsis-Mortari A, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127:2144–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138:2278–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riches DW, Backos DS, Redente EF. ROCK and Rho: Promising therapeutic targets to ameliorate pulmonary fibrosis. Am J Pathol. 2015;185:909–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Przepiorka D, Le RQ, Ionan A, Lii EJ, Qang YH, Gudi R, et al. FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy. Clin Cancer Res. 2022;28:2488–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Michonneau D, Malard F, Le Grand S, Magro L, D’Aveni M, Tudesq JJ, et al. Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transpl. 2025;60:779–86.

Article  CAS  Google Scholar 

Modi B, Ngo D, Chen J, Yang D, Shan H, Sandhu K, et al. Belumosudil for the treatment of chronic graft-versus-host disease: a single center real-world experience. Bone Marrow Transpl. 2025;60:555–7.

Article  Google Scholar 

Heidenreich S, Egger-Heidrich K, Halter JP, Jost L, Stölzel F, Perl M, et al. Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis. Bone Marrow Transpl. 2025;60:439–46.

Article  CAS  Google Scholar 

Chin MM, Tamaresis JS, Johnston LJ, Lowsky R, Meyer E, Muffly L, et al. Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice. Bone Marrow Transpl. 2025;60:393–5.

Article  Google Scholar 

Dierov D, Webb N, Fatmi S, Nwanne Cm Ciolino C, Mosesso K, et al. Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria. Adv Cell Gene Ther. 2019;2:62.

Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl. 2018;53:1401–15.

Article  Google Scholar 

Copelan E, Casper JT, Carter SL, van Burik JAH, Hurd D, Mendizabal AM, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transpl. 2007;13:1469–76.

Article  Google Scholar 

Keever-Taylor C, Devine S, Soiffer R, Mendizabal A, Carter S, Pasquini MC, et al. Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transpl. 2012;18:690–7.

Article  Google Scholar 

DeFilipp Z, Alousi AM, Pidala JA, Carpenter PA, Onstad LE, Arai S, et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Adv. 2021;5:4278–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saidu NEB, Bonini C, Dickinson A, Grce M, Inngjerdingen M, Koehl U, et al. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. Front Immunol. 2020;11:578314.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia. 2020;34:1229–40.

Article  PubMed  PubMed Central  Google Scholar 

Wolff D, Radojcic V, Lafyatis R, Cinar R, Rosenstein RK, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. Transpl Cell Ther. 2021;27:817–35.

Article  Google Scholar 

Lee SJ, Cutler C, Blazar BR, Tu A, Yang Z, Pavletic SZ. Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies. Transpl Cell Ther. 2022;28:700 e701–700.e706.

Article  Google Scholar 

Inamoto Y, Kato K, Kawakita T, Onishi Y, Matsuoka KI, Shiratori S, et al. An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD. Am J Hematol. 2024;99:1917–26.

Article  CAS  PubMed  Google Scholar